Advertisement

Current approaches to acute promyelocytic leukemia

  • Stanley R. Frankel
  • Bayard L. Powell
Part of the Cancer Treatment and Research book series (CTAR, volume 99)

Abstract

Acute promyelocytic leukemia (APL), the M3 subtype of acute myeloid leukemia (AML) in the French—American—British (FAB) classification system [1], is a distinct clinical and pathologic subtype that accounts for approximately 10% of acute myeloid leukemia (AML) cases. The unique features of APL have been well described [2, 3, 4] and include a characteristic morphologic appearance [5], a reciprocal translocation between the long arms of chromosomes 15 and 17 [6], younger age of onset [7], and severe consumptive coagulopathy with a high incidence of early fatal hemorrhage [3,8]–10. This coagulopathy is frequently exacerbated by cytotoxic chemotherapy, probably a result of leukemia cell lysis with release of procoagulant intracellular contents [11,12].

Keywords

Acute Myeloid Leukemia Retinoic Acid Acute Promyelocytic Leukemia Acute Promyelocytic Leukemia Cell Retinoic Acid Receptor Alpha 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bennett J, Catovsky D, Daniel M, Flandrin G, Galton D, Gralnick H, Sultan C. 1985. Proposed revised criteria for the classification of acute myeloid leukemia. Ann Intern Med 103:626–629.Google Scholar
  2. 2.
    Warrell RP Jr, de The H, Wang ZY, Degos L. 1993. Acute promyelocytic leukemia. N Engl J Med 329:177–189.PubMedCrossRefGoogle Scholar
  3. 3.
    Stone RM, Mayer RJ. 1990. The unique aspects of acute promyelocytic leukemia. J Clin Oncol 8:1913–1921.PubMedGoogle Scholar
  4. 4.
    Frankel SR. 1993. Acute promyelocytic leukemia: new insights into diagnosis and therapy. Hematol Oncol Clin North Am 7:109–138.PubMedGoogle Scholar
  5. 5.
    Davey FR, Davis RB, MacCallum JM, Nelson DA, Mayer RJ, Ball ED, Griffin JD, Schiffer CA, Bloomfield CD. 1989. Morphologic and cytochemical characteristics of acute promyelocytic leukemia. Am J Hematol 30:221–227.PubMedCrossRefGoogle Scholar
  6. 6.
    Larson RA, Kondo K, Vardiman J, Butler AE, Golomb HM, Rowley JD. 1984. Evidence for a 15; 17 translocation in every patient with acute promyelocytic leukemia. Am J Med 76:827–841.PubMedCrossRefGoogle Scholar
  7. 7.
    Mertelsmann R, Tzvi Thaler H, To L, Gee TS, McKenzie S, Schauer P, Arlin Z, Cirrincione C, Clarkson B. 1980. Morphological classification, response to therapy, and survival in 263 adult patients with acute nonlymphoblastic leukemia. Blood 56:773–781.PubMedGoogle Scholar
  8. 8.
    Ventura GJ, Hester JP, Dixon DO, Khorana S, Keating MJ. 1989. Analysis of risk factors for fatal hemorrhage during induction therapy of patients with acute promyelocytic leukemia. Hematol Pathol 3:23–28.PubMedGoogle Scholar
  9. 9.
    Tallman MS, Hakimian D, Kwaan HC, Rickles FR. 1993. New insights into the pathogenesis of coagulation dysfunction in acute promyelocytic leukemia. Leuk Lymphoma 11:27–36.PubMedCrossRefGoogle Scholar
  10. 10.
    DeLoughery TG, Goodnight SH. 1996. Acute promyelocytic leukaemia in the all trans retinoic acid era. Med Oncol 13:233–240.PubMedCrossRefGoogle Scholar
  11. 11.
    Sanz MA, Jarque I, Martin G, Lorenzo I, Martinez J, Rafecas J, Pastor E, Sayas MJ, Sanz G, Gomis F. 1988. Acute promyelocytic leukemia: therapy results and prognostic factors. Cancer 61:7–13.PubMedCrossRefGoogle Scholar
  12. 12.
    Gralnick HR, Sultan C. 1975. Acute promyelocytic leukemia: haemorrhagic manifestation and morphologic criteria. Br J Haematol 29:373–376.PubMedGoogle Scholar
  13. 13.
    McKenna RW, Parkin J, Bloomfield CD, Sundberg RD, Brunning RD. 1982. Acute promyelocytic leukaemia: a study of 39 cases with identification of a hyperbasophilic microgranular variant. Br J Haematol 50:201–214.PubMedGoogle Scholar
  14. 14.
    Neame PB, Soamboonsrup P, Leber B, Carter RF, Sunisloe L, Patterson W, Orzel A, Bates S, McBride JA. 1997. Morphology of acute promyelocytic leukemia with cytogenetic or molecular evidence for the diagnosis: characterization of additional microgranular variants. Am J Hematol 56:131–142.PubMedCrossRefGoogle Scholar
  15. 15.
    Guglielmi C, Martelli MP, Diverio D, Fenu S, Vegna ML, Cantù-Rajnoldi A, Biondi A, Cocito MG, Del Vecchio L, Tabilio A, Basso G, Lo Coco F. 1997. Immunophenotype of adult and childhood acute promyelocytic leukemia: correlation with morphology and type of PML gene breakpoint. A cooperative Italian study on 196 cases. Blood 90:3694. (abstract)Google Scholar
  16. 16.
    Speicher MR, Jauch A, Parr AS, Becher R. 1993. Delineation of translocation t(15;17) in acute promyelocytic leukemia by chromosomal in situ suppression hybridization. Leuk Res 17:359–364.PubMedCrossRefGoogle Scholar
  17. 17.
    Mancini M, Nanni M, Cedrone M, Diverio D, Avvisati G, Riccioni R, De Cuia MR, Fenu S, Alimena G. 1995. Combined cytogenetic, FISH and molecular analysis in acute promyelocytic leukaemia at diagnosis and in complete remission. Br J Haematol 91:878–884.PubMedGoogle Scholar
  18. 18.
    Eclache V, Benzacken B, Le Roux G, Casassus P, Chomienne C. 1997. PML/RAR alpha rearrangement in acute promyelocytic leukaemia with t(1;17) elucidated using fluorescence in situ hybridization. Br J Haematol 98:440–443.PubMedCrossRefGoogle Scholar
  19. 19.
    Vyas RC, Frankel SR, Agbor P, Miller WH Jr, Warrell RP Jr, Hittelman WN. 1996. Probing the pathobiology of response to all-trans retinoic acid in acute promyelocytic leukemia: premature chromosome condensation/flourescence in situ hybridization analysis. Blood 87:218–226.PubMedGoogle Scholar
  20. 20.
    McKinney CD, Golden WL, Gemma NW, Swerdlow SH, Williams ME. 1994. RARA and PML gene rearrangements in acute promyelocytic leukemia with complex translocations and atypical features. Genes Chromosomes Cancer 9:49–56.PubMedCrossRefGoogle Scholar
  21. 21.
    Ikeda K, Sasaki K, Tasaka T, Nagai M, Kawanishi K, Takahara J, Irino S. 1994. Detection of PML-retinoic acid receptor-alpha fusion transcripts in acute promyelocytic leukemia with trisomy 8 but without t(15;17). Am J Hematol 45:212–216.PubMedCrossRefGoogle Scholar
  22. 22.
    Miller WH Jr, Levine K, DeBlasio A, Frankel SR, Dmitrovsky E, Warrell RP Jr. 1993. Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcription polymerase chain reaction assay for the PML/RAR-alpha fusion mRNA. Blood 82:1689–1694.PubMedGoogle Scholar
  23. 23.
    Miller WH Jr, Kakizuka A, Frankel SR, Warrell RP Jr, DeBlasio A, Levine K, Evans RM, Dmitrovsky E. 1992. Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor alpha clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia. Proc Natl Acad Sci U S A 89:2694–2698.PubMedCrossRefGoogle Scholar
  24. 24.
    Grimwade D, Gorman P, Duprez E, Howe K, Langabeer S, Oliver F, Walker H, Culligan D, Waters J, Pomfret M, Goldstone A, Burnett A, Freemont P, Sheer D, Solomon E. 1997. Characterization of cryptic rearrangements and variant translocations in acute promyelocytic leukemia. Blood 90:4876–4885.PubMedGoogle Scholar
  25. 25.
    Diverio D, Riccioni R, Pistilli A, Buffolino S, Avvisati G, Mandelli F, Lo Coco F. 1996. Improved rapid detection of the PML/RARalpha fusion gene in acute promyelocytic leukemia. Leukemia 10:1214–1216.PubMedGoogle Scholar
  26. 26.
    Falini B, Flenghi L, Fagioli M, Coco FL, Cordone I, Diverio D, Pasqualucci L, Biondi A, Riganelli D, Orleth A, Liso A, Martelli MF, Pelicci PG, Pileri S. 1997. Immunocytochemical diagnosis of acute promyelocytic leukemia (M3) with the monoclonal antibody PG-M3 (anti-PML). Blood 90:4046–4053.PubMedGoogle Scholar
  27. 27.
    Grimwade D, Howe K, Langabeer S, Davies L, Oliver F, Walker H, Swirsky D, Wheatley K, Goldstone A, Burnett A, Solomon E. 1996. Establishing the presence of the t(15;17) in suspected acute promyelocytic leukaemia: cytogenetic, molecular and PML immunofluorescence assessment of patients entered into the M.R.C. ATRA trial. M.R.C. Adult Leukaemia Working Party. Br J Haematol 94:557–573.PubMedGoogle Scholar
  28. 28.
    Ferrucci PF, Grignani F, Pearson M, Fagioli M, Nicoletti I, Pelicci PG. 1997. Cell death induction by the acute promyelocytic leukemia-specific PML/RARalpha fusion protein. Proc Natl Acad Sci U S A 94:10901–10906.PubMedCrossRefGoogle Scholar
  29. 29.
    Warrell RP Jr, Frankel SR, Miller WH Jr, Scheinberg DA, Itri LM, Hittelman WN, Vyas R, Andreeff M, Agostino T, Jakubowski A, Gabrilove J, Gordon MS, Dmitrovsky E. 1991. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 324:1385–1393.PubMedCrossRefGoogle Scholar
  30. 30.
    Chen Z, Xue Y, Zhang R, Tao R, Xia X, Li C, Wang W, Zu W, Yao X, Ling B. 1991. A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients. Blood 78:1413–1419.PubMedGoogle Scholar
  31. 31.
    Meng-er H, Yu-chen Y, Shu-rong C, Jin-ren C, Jia-Xiang L, Lin Z, Long-jun G, Zhen-yi W. 1988. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72:567–572.Google Scholar
  32. 32.
    Degos L, Chomienne C, Daniel MT, Berger R, Dombret H, Fenaux P, Castaigne S. 1990. Treatment of first relapse in acute promyelocytic leukaemia with all-trans retinoic acid. Lancet 336:1440–1441.PubMedCrossRefGoogle Scholar
  33. 33.
    Castaigne S, Chomienne C, Daniel MT, Ballerini P, Berger R, Fenaux P. 1990. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. Blood 76:1704–1709.PubMedGoogle Scholar
  34. 34.
    Tosi P, Visani G, Ottaviani E, Pellacani A, Manfroi S, Tura S. 1996. Retinoids increase idarubicin cytotoxicity in human myeloid leukemia cell lines. Anticancer Drugs 7:774–779.PubMedCrossRefGoogle Scholar
  35. 35.
    Sporn MB, Roberts AB. 1983. Role of retinoids in differentiation and carcinogenesis. Cancer Res 43:3034–3040.PubMedGoogle Scholar
  36. 36.
    Tabin C. 1991. Retinoids, homeoboxes, and growth factors: toward molecular models for limb development. Cell 66:199–217.PubMedCrossRefGoogle Scholar
  37. 37.
    Phillips WEJ, Murray TK, Campbell JS. 1970. Serum vitamin A and carotenoids of Canadians. Can Med Assoc J 102:1085–1086.PubMedGoogle Scholar
  38. 38.
    Muindi JR, Frankel SR, Huselton C, DeGrazia F, Garland WA, Young CW Jr. 1992. Clinical pharmacology of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. Cancer Res 52:2138–2142.PubMedGoogle Scholar
  39. 39.
    Lefebvre P, Thomas G, Gourmel B, Agadir A, Castaigne S, Dreux C, Degos L, Chomienne C. 1991. Pharmacokinetics of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. Leukemia 5:1054–1058.PubMedGoogle Scholar
  40. 40.
    Kizaki M, Ueno H, Yamazoe Y, Shimada M, Takayama N, Muto A, Matsushita H, Nakajima H, Morikawa M, Koeffler HP, Ikeda Y. 1996. Mechanisms of retinoid resistance in leukemic cells: possible role of cytochrome P450 and P-glycoprotein. Blood 87:725–733.PubMedGoogle Scholar
  41. 41.
    Rowe JM, Andersen JW, Cassileth PA, Oken MM, Bennett JM, Wiernik PH. 1992. Post-remission therapy in adults with acute myelogenous leukemia: the Eastern Cooperative Oncology Group (ECOG) experience. Leukemia 6(Suppl 4):75–77.PubMedGoogle Scholar
  42. 42.
    Usuki K, Endo M, Osawa M, Kitazume K, Iki S, Urabe A. 1996. Pharmacokinetics of all-trans-retinoic acid in Japanese patients with acute promyelocytic leukemia. Int J Hematol 63:19–23.PubMedCrossRefGoogle Scholar
  43. 43.
    Chen GQ, Shen ZX, Wu F, Han JY, Miao JM, Zhong HJ, Li XS, Zhao JQ, Zhu J, Fang ZW, Chen SJ, Chen Z, Wang ZY. 1996. Pharmacokinetics and efficacy of low-dose all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Leukemia 10:825–828.PubMedGoogle Scholar
  44. 44.
    Castaigne S, Lefebvre P, Rigal-Huguet F, Gardin C, Montfort L, Suc E, Delmer A, Troncy J, Tilly H, Travade P, Gilles E, Rapp MJ, Montastruc M, Isnard F, Weh H, Christian B, Janvier M, Dombret H, Fenaux P, Chomienne C, Degos L. 1992. Lower all trans retionic acid (ATRA 25mg/m2/day) are effective in acute promyelocytic leukemia. Blood 80(Suppl 1):360a. (abstract)Google Scholar
  45. 45.
    Muindi J, Frankel SR, Miller WH Jr, Jakubowski A, Scheinberg DA, Young CW, Dmitrovsky E, Warrell RP Jr. 1992. Continuous treatment with all-trans retinoic acid results in a progressive decrease in plasma concentrations: implications for relapse and ‘resistance’ in acute promyelocytic leukemia. Blood 79:299–303.PubMedGoogle Scholar
  46. 46.
    Adamson PC, Boylan JF, Balis FM, Murphy RF, Godwin KA, Gudas LJ. 1993. Time course of induction of metabolism of all-trans-retinoic acid and the up-regulation of cellular retinoic acid-binding protein. Cancer Research 53:472–476.PubMedGoogle Scholar
  47. 47.
    Cornic M, Delva L, Castaigne S, Lefebvre P, Balitrand N, Degos L. 1994. In vitro all-trans retinoic acid (ATRA) sensitivity and cellular retinoic acid binding protein (CRABP) levels in relapse leukemic cells after remission induction by ATRA in acute promyelocytic leukemia. Leukemia 8(Suppl 2):S16–19.PubMedGoogle Scholar
  48. 48.
    Takitani K, Tamai H, Morinobu T, Kawamura N, Miyake M, Fujimoto T, Mino M. 1995. 4-oxo retinoic acid for refractory acute promyelocytic leukemia in children with all-trans retinoic acid therapy. J Nutr Sci Vitaminol (Tokyo) 41:493–498.Google Scholar
  49. 49.
    Lazzarino M, Regazzi MB, Corso A. 1996. Clinical relevance of all-trans retinoic acid pharmacokinetics and its modulation in acute promyelocytic leukemia. Leuk Lymphoma 23:539–543.PubMedCrossRefGoogle Scholar
  50. 50.
    Marini G, Caccia S, Guiso G, Luciano A, Sessa C. 1995. Long-term remission of acute promyelocytic leukemia with intermittent all-trans-retinoic acid: a case report. Ann Oncol 6:732–734. (letter)PubMedGoogle Scholar
  51. 51.
    Adamson PC, Bailey J, Pluda J, Poplack DG, Bauza S, Murphy RF, Yarchoan R, Balis FM. 1995. Pharmacokinetics of all-trans-retinoic acid administered on an intermittent schedule. J Clin Oncol 13:1238–1241.PubMedGoogle Scholar
  52. 52.
    Bargetzi MJ, Tichelli A, Gratwohl A, Speck B. 1996. Oral All-transretinoic acid administration in intubated patients with acute promyelocytic leukemia. Schweiz Med Wochenschr 126:1944–1945.PubMedGoogle Scholar
  53. 53.
    Niitsu N, Yamamoto-Yamaguchi Y, Kanatani Y, Shuto S, Matsuda A, Umeda M, Honma Y. 1997. Neplanocin A, a potent inhibitor of S-adenosylhomocysteine hydrolase, potentiates granulocytic differentiation of acute promyelocytic leukemia cells induced by all-trans retinoic acid. Exp Hematol 25:1296–1303.PubMedGoogle Scholar
  54. 54.
    Yaguchi M, Miyazawa K, Katagiri T, Nishimaki J, Kizaki M, Tohyama K, Toyama K. 1997. Vitamin K2 and its derivatives induce apoptosis in leukemia cells and enhance the effect of all-trans retinoic acid. Leukemia 11:779–787.PubMedCrossRefGoogle Scholar
  55. 55.
    Elstner E, Linker-Israeli M, Le J, Umiel T, Michl P, Said JW, Binderup L, Reed JC, Koeffler HP. 1997. Synergistic decrease of clonal proliferation, induction of differentiation, and apoptosis of acute promyelocytic leukemia cells after combined treatment with novel 20-epi vitamin D3 analogs and 9-cis retinoic acid. J Clin Invest 99:349–360.PubMedGoogle Scholar
  56. 56.
    Breitman TR, Selonick SE, Collins SJ. 1980. Induction of differentiation of the human promyelocytic leukemia cell line (HL60) by retinoic acid. Proc Natl Acad Sci USA 77:2936–2940.PubMedCrossRefGoogle Scholar
  57. 57.
    Breitman TR, Collins SJ, Keene BR. 1981. Terminal differentiation of human promyelocytic leukemic cells in primary culture in response to retinoic acid. Blood 57:1000–1004.PubMedGoogle Scholar
  58. 58.
    Nilsson B. 1984. Probable in vivo induction of differentiation by retinoic acid of promyelocytes in acute promyelocytic leukemia. Br J Haematol 57:365–371.Google Scholar
  59. 59.
    Fontana JA, Rogers JS, Durham JP. 1989. The role of 13-cis retinoic acid in the remission induction of a patient with acute promyelocytic leukemia. Cancer 57:209–217.CrossRefGoogle Scholar
  60. 60.
    Huang ME, Ye YC, Chen SR, Zhao JC, Gu LJ, Cai JR, Zhao L, Xie JX, Wang ZY. 1987. All-trans retinoic acid with or without low dose cytosine arabinoside in acute promyelocytic leukemia. Report of 6 cases. Chin Med J 100:949–953.PubMedGoogle Scholar
  61. 61.
    Huang ME, Ye YC, Chen SR, Chai JR, Lu HX, Zhoa L, Gu LJ, Wang ZY. 1988. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72:567–572.PubMedGoogle Scholar
  62. 62.
    Frankel SR. 1994. Retinoic acid: from bench to bedside. Adv Oncol 10(2):23–29.Google Scholar
  63. 63.
    Fenaux P, Chomienne C, Degos L. 1997. Acute promyelocytic leukemia: biology and treatment. Semin Oncol 24:92–102.PubMedGoogle Scholar
  64. 64.
    Lo Coco F, Avvisati G, Diverio D, Petti MC, Alcalay M, Pandolfi PP, Zangrilli D, Biondi A, Rambaldi A, Moleti ML. 1991. Molecular evaluation of response to all-trans-retinoic acid therapy in patients with acute promyelocytic leukemia. Blood 77:1657–1659.Google Scholar
  65. 65.
    National Cooperative Study Group on Treatment of Leukemias. 1992. Clinical study on all-trans retinoic acid. Chin J Hematol 13:135–137.Google Scholar
  66. 66.
    Castaigne S, Chomienne C, Daniel MT, Ballerini P, Berger R, Fenaux P, Degos L. 1990. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 76:1704–1709.Google Scholar
  67. 67.
    Fenaux P, Castaigne S, Dombret H, Archimbaud E, Duarte M, Morel P, Tilly H, Guerci A, Maloisel F, Bordessoule D, Sandoun A, Tiberghien P, Fegueux N, Daniel MT, Chomienne C, Degos L. 1992. All-trans retinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: A pilot study on 26 cases. Blood 80:2176–2181.PubMedGoogle Scholar
  68. 68.
    Wiley JS, Firkir FG. 1992. A phase I study of all-trans retinoic acid for remission induction of poor risk acute promyelocytic leukemia. Blood 80(Suppl 1):463a. (abstract)Google Scholar
  69. 69.
    Hernandez P, Carnot J, Dorticos E, Espinosa E, Gonzalez A, Rodriguezl. 1992. All-trans retinoic acid in acute promyelocytic leukemia: preliminary results in Cuba. Ann Hematol 65:121–123.PubMedCrossRefGoogle Scholar
  70. 70.
    Light SE, Stevenson HC, Parkinson DR, Schnipper EF. 1992. Phase II trial of all trans retinoic acid (ATRA) in acute promyelocytic leukemia (APL). Proc Am Soc Clin Oncol 11:263. (abstract)Google Scholar
  71. 71.
    Frankel SR, Eardley A, Heller G, Berman E, Miller WH Jr, Dmitrovsky E, Warrell RP Jr. 1994. All-trans retinoic acid for acute promyelocytic leukemia. Results of the New York Study. Ann Intern Med 120:278–286.PubMedGoogle Scholar
  72. 72.
    Dombret H, Castaigne S, Fenaux P, Chomienne C, Degos L. 1994. Induction treatment of acute promyelocytic leukemia using all-trans retinoic acid. Controversies about dosage, advantages and side-effect management. Leukemia 8(Suppl 3):S73–75.PubMedGoogle Scholar
  73. 73.
    Fenaux P, Degos L. 1996. Treatment of acute promyelocytic leukaemia. Baillieres Clin Haematol 9:107–128.PubMedCrossRefGoogle Scholar
  74. 74.
    Asou N, Adachi K, Tamura J, Kanamaru A, Kageyama S, Hiraoka A, Omoto E, Sakamaki H, Tsubaki K, Saito K, Ohno R. 1997. All-trans retinoic acid therapy for newly diagnosed acute promyelocytic leukemia: comparison with intensive chemotherapy. The Japan Adult Leukemia Study Group (JALSG). Cancer Chemother Pharmacol 40(Suppl):S30–S35.PubMedCrossRefGoogle Scholar
  75. 75.
    Kanamaru A, Takemoto Y, Tanimoto M, et al. 1995. All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Japan Adult Leukemia Study Group. Blood 85:1202–1206.PubMedGoogle Scholar
  76. 76.
    Soignet S, Fleischauer A, Polyak T, Heller G, Warrell RP Jr. 1997. All-trans retinoic acid significantly increases 5-year survival in patients with acute promyelocytic leukemia: long-term follow-up of the New York study. Cancer Chemother Pharmacol 40(Suppl): S25–S29.PubMedCrossRefGoogle Scholar
  77. 77.
    Ohno R, Ohnishi K, Takeshita A, Tanimoto M, Murakami H, Kanamaru A, Asou N, Kobayashi T, Kuriyama K, Ohmoto E. 1994. All-trans retinoic acid therapy in relapsed/ refractory or newly diagnosed acute promyelocytic leukemia (APL) in Japan. Leukemia 8(Suppl 3):S64–S69.PubMedGoogle Scholar
  78. 78.
    Warrell RP Jr, Maslak P, Eardley A, Heller G, Miller WH Jr, Frankel SR. 1994. Treatment of acute promyelocytic leukemia with all-trans retinoic acid: an update of the New York experience. Leukemia 8:929–933.PubMedGoogle Scholar
  79. 79.
    Mandelli F, Diverio D, Avvisati G, Luciano A, Barbui T, Bernasconi C, Broccia G, Cerri R, Falda M, Fioritoni G, Leoni F, Liso V, Petti MC, Rodeghiero F, Saglio G, Vegna ML, Visani G, Jehn U, Willemze R, Muus P, Pelicci PG, Biondi A, Lo Coco F. 1997. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell’Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood 90:1014–1021.PubMedGoogle Scholar
  80. 80.
    Avvisati G, Lo Coco F, Diverio D, Falda M, Ferrara F, Lazzarino M, Russo D, Petti MC, Mandelli F. 1996. AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto (GIMEMA) pilot study. Blood 88:1390–1398.PubMedGoogle Scholar
  81. 81.
    Lo Coco F, Diverio D, Avvisati G, Luciano A, De Santis S, Santoro A, Pane F, Martinelli G, Pelicci PG, Vega ML, Saglio G, Biondi A, Mandelli F, the GIMEMA and AIEOP Cooperative Groups. 1997. Prospective RT-PCR monitoring of minimal residual disease in acute promyelocytic leukemia patients enrolled in the multicentric GIMEMA-AIEOP ‘AIDA’ trial. Blood 90(Suppl 1):390a. (abstract)Google Scholar
  82. 82.
    Estey E, Thall PF, Pierce S, Kantarjian H, Keating M. 1997. Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine. J Clin Oncol 15:483.PubMedGoogle Scholar
  83. 83.
    Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, Shepherd L, Willman C, Bloomfield CD, Rowe JM, Wiernik PH. 1997. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 337:1021.PubMedCrossRefGoogle Scholar
  84. 84.
    Asou N, Adachi K, Tamura J, Kanamaru A, Kageyama S, Hiraoka A, Omoto E, Akiyama H, Tsubaki K, Saito K, Kuriyama K, Oh H, Kitano K, Miyawaki S, Takeyama K, Yamada O, Nishikawa K, Takahashi M, Matsuda S, Ohtake S, Suzushima H, Emi N, Ohno R. 1998. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group. J Clin Oncol 16:78–85.PubMedGoogle Scholar
  85. 85.
    Chim CS, Kwong YL, Liang R, Chu YC, Chan CH, Chan LC, Wong KF, Chan TK. 1996. All-trans retinoic acid (ATRA) in the treatment of acute promyelocytic leukemia (APL). Hematol Oncol 14:147–154.PubMedCrossRefGoogle Scholar
  86. 86.
    Jurcic JG, DeBlasio A, Dumont L, Warrell RP Jr, Scheinberg DA. 1997. Molecular remission induction without relapse after anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia. Blood 90(Suppl l):416a. (abstract)Google Scholar
  87. 87.
    Fenaux P, Le Deley MC, Castaigne S, Archimbaud E, Chomienne C, Link H, Guerci A, Duarte M, Daniel MT, Bowen D, Huebner G, Bauters F, Fegueux N, Fey M, Sanz M, Lowenberg B, Maloisel F, Auzanneau G, Sadoun A, Gardin C, Bastion Y, Ganser A, Jacky E, Dombret H, Chastang C, Degos L, European APL 91 Group. 1993. Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. Blood 82:3241–3249.Google Scholar
  88. 88.
    Fenaux P, Chastang C, Castaigne S, Archimbaud E, Link H, Fey M, Guerci A, Fegueux N, Bowen D, Löwenberg B. 1997. Long-term follow-up confirms the superiority of ATRA combined to chemotherapy over CT alone in newly diagnosed acute promyelocytic leukemia (APL). Blood 90(Suppl 1):331a.Google Scholar
  89. 89.
    Fenaux P, Chastang C, Sanz M, Thomas X, Dombret H, Link H, Guerci A, Fegueux N, San Miguel J, Rayon C, et al, the European APL Group. 1997. ATRA followed by chemotherapy (CT) versus ATRA plus CT, and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia (APL): first interim results of APL 93 trial. Blood 90(Suppl 1):122a. (abstract)Google Scholar
  90. 90.
    Estey E, Andreeff M, O’Brien S, Kantarjian H. 1995. Treatment of newly-diagnosed acute promyelocytic leukemia (APL) without cytosine arabinoside (ara-C). Blood 86(Suppl 1):266a. (abstract)Google Scholar
  91. 91.
    Burnett AK, Goldstone AH, Gray RG, Wheatley K. 1997. All-trans-retinoic acid given concurrently with induction chemotherapy improves the outcome of APL: results of the UK MRC ATRA trial. Blood 90(Suppl 1):330a. (abstract)Google Scholar
  92. 92.
    Nucifora E, Fantl D, Goldstein S, Kusminsky G. 1996. Acute promyelocytic leukemia: experience with trans-retinoic acid in Argentina. Medicina (B Aires) 56:333–338.Google Scholar
  93. 93.
    Wiley JS, Firkin FC. 1995. Reduction of pulmonary toxicity by prednisolone prophylaxis during all-trans retinoic acid treatment of acute promyelocytic leukemia. Australian Leukemia Study Group. Leukemia 9:774–778.PubMedGoogle Scholar
  94. 94.
    Head D, Kopecky KJ, Weick J, Files JC, Ryan D, Foucar K, Montiel M, Bickers J, Fishleder A, Miller M. 1995. Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia. Blood 86:1717–1728.PubMedGoogle Scholar
  95. 95.
    Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, Omura GA, Moore JO, McIntyre OR, Frei E III. 1994. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 331:896.PubMedCrossRefGoogle Scholar
  96. 96.
    Bloomfield C, Lawrence D, Arthur D, Berg D, Schiffer C, Mayer R. 1994. Curative impact of intensification with high dose cytarabine in acute myeloid leukemia varies by cytogenetic group. Blood 84(Suppl 1):431a.Google Scholar
  97. 97.
    Lengfelder E, Reichert A, Hehlmann R, Löffler AH, Fonatsch C, Schoch C, Staib P, Seifarth W, Sauerland MC, Heinecke A, Wörmann B, Hiddemann W, Büchner T, the German Acute Myeloid Leukemia Cooperative Group (AMLCG). 1997. Effects of high-dose cytarabine as part of double induction strategy in acute promyelocytic leukemia and results of combination with all-trans-retinoic acid. Blood 90(Suppl 1):330a. (abstract)Google Scholar
  98. 98.
    Seiter K, Feldman E, Miller WH Jr, DeBlasio A, Levine K, Ahmed T, Arlin Z. 1993. All trans retinoic acid (ATRA) following induction chemotherapy for acute promyelocytic leukemia (APL). Blood 82(Suppl 1):250a. (abstract)Google Scholar
  99. 99.
    Seiter K, Miller WH Jr, Feldman EJ, Ahmed T, Arlin Z. 1995. Pilot study of all-trans retinoic acid as post-remission therapy in patients with acute promyelocytic leukemia. Leukemia 9:15–18.PubMedGoogle Scholar
  100. 100.
    Jurcic JG, Caron PC, Miller WH Jr, Yao TJ, Maslak P, Finn R, Larson SM, Warrell RP Jr, Scheinberg DA. 1993. I-labeled anti-CD33(I-M195) may prolong disease-free survival in relapsed acute promyelocytic leukemia after remission induction with all-trans retinoic acid. Blood 82(Suppl 1):193a. (abstract)Google Scholar
  101. 101.
    Jurcic JG, Caron PC, Miller WH Jr, Yao TJ, Maslak P, Finn RD, Larson SM, Warrell RP Jr, Scheinberg DA. 1995. Sequential targeted therapy for relapsed acute promyelocytic leukemia with all-trans retinoic acid and anti-CD33 monoclonal antibody M195. Leukemia 9:244–248.PubMedGoogle Scholar
  102. 102.
    Taylor P, Jackson G, Vickers M, Ross J, Gorst D, Clough V, Bown N, Reid M, Proctor S, the 4 Regions Leukaemia Register Group. 1997. A population-based study on the effect of age, WBC, cytogenetics and ATRA on outcome in acute promyelocytic leukaemia. Blood 90(Suppl 1):3792a. (abstract)Google Scholar
  103. 103.
    Pollicardo N, O’Brien S, Estey EH, al-Bitar M, Pierce S, Keating M, Kantarjian HM. 1996. Secondary acute promyelocytic leukemia. Characteristics and prognosis of 14 patients from a single institution. Leukemia 10:27–31.PubMedGoogle Scholar
  104. 104.
    Gillis S, Sofer O, Zelig O, Dann EJ, Lotan H, Ben Yehuda D, Isacson R, Rachmilewitz EA, Ben-Bassat I, Polliack A. 1995. Acute promyelocytic leukaemia with t(15;17) following treatment of Hodgkin’s disease — a report of 4 cases. Ann Oncol 6:777–779.PubMedGoogle Scholar
  105. 105.
    Yoshioka K, Yamaguchi M, Kasamatsu Y, Ashida K, Yokoh S, Tatebe A, Yoshida T, Kondo M. 1997. Acute promyelocytic leukemia following leiomyosarcoma of the jejunum. Arch Intern Med 157:1392–1393. (letter)PubMedCrossRefGoogle Scholar
  106. 106.
    Slack JL, Arthur DC, Lawrence D, Mrozek K, Mayer RJ, Davey FR, Tantravahi R, Pettenati MJ, Bigner S, Carroll AJ, Rao KW, Schiffer CA, Bloomfield CD. 1997. Secondary cytogenetic changes in acute promyelocytic leukemia — prognostic importance in patients treated with chemotherapy alone and association with the intron 3 breakpoint of the PML gene: a Cancer and Leukemia Group B study. J Clin Oncol 15:1786–1795.PubMedGoogle Scholar
  107. 107.
    Hiorns LR, Swansbury GJ, Mehta J, Min T, Dainton MG, Treleaven J, Powles RL, Catovsky D. 1997. Additional chromosome abnormalities confer worse prognosis in acute promyelocytic leukaemia. Br J Haematol 96:314–321.PubMedCrossRefGoogle Scholar
  108. 108.
    Schoch C, Haase D, Haferlach T, Freund M, Link H, Lengfelder E, Loffler H, Buchner T, Fonatsch C. 1996. Incidence and implication of additional chromosome aberrations in acute promyelocytic leukaemia with translocation t(15;17)(q22;q21): a report on 50 patients. Br J Haematol 94:493–500.PubMedCrossRefGoogle Scholar
  109. 109.
    Nagao K, Kikuchi A, Kawai Y, Kizaki M, Ikeda Y, Nishikawa T. 1997. Skin infiltration in acute promyelocytic leukemia. Dermatology 194:168–171.PubMedCrossRefGoogle Scholar
  110. 110.
    Kishimoto S, Ishii E, Murakami Y, Takeshita M, Watanabe M, Sakai R, Miyazaki S. 1997. Cutaneous infiltration by leukemic cells in acute promyelocytic leukemia of a child after treatment with all-trans retinoic acid. Pediatr Hematol Oncol 14:169–175.PubMedCrossRefGoogle Scholar
  111. 111.
    Ueda K, Kume A, Furukawa Y, Higashi N. 1997. Cutaneous infiltration in acute promyelocytic leukemia. J Am Acad Dermatol 36:104–106.PubMedCrossRefGoogle Scholar
  112. 112.
    Lammer EJ, Chen DT, Hoar RM, et al. 1985. Retinoic acid embryopathy. N Engl J Med 313:837–841.PubMedCrossRefGoogle Scholar
  113. 113.
    Stentoft J, Nielsen JL, Hvidman LE. 1994. All-trans retinoic acid in acute promyelocytic leukemia in late pregnancy. Leukemia 8(Suppl 2):S77–S80.PubMedGoogle Scholar
  114. 114.
    Harrison P, Chipping P, Fothergill GA. 1994. Successful use of all-trans retinoic acid in acute promyelocytic leukaemia presenting during the second trimester of pregnancy. Br J Haematol 86:681–682.PubMedGoogle Scholar
  115. 115.
    Incerpi MH, Miller DA, Posen R, Byrne JD. 1997. All-trans retinoic acid for the treatment of acute promyelocytic leukemia in pregnancy. Obstet Gynecol 89:826–828.PubMedCrossRefGoogle Scholar
  116. 116.
    Lipovsky MM, Biesma DH, Christiaens GC, Petersen EJ. 1996. Successful treatment of acute promyelocytic leukaemia with all-trans-retinoic-acid during late pregnancy. Br J Haematol 94:699–701.PubMedCrossRefGoogle Scholar
  117. 117.
    Maeda M, Tyugu H, Okubo T, Yamamoto M, Nakamura K, Dan K. 1997. A neonate born to a mother with acute promyelocytic leukemia treated by all-trans retinoic acid. Rinsho Ketsueki 38:770–775.PubMedGoogle Scholar
  118. 118.
    Hatake K, Uwai M, Ohtsuki T, Tomizuka H, Izumi T, Yoshida M, Miura Y. 1997. Rare but important adverse effects of all-trans retinoic acid in acute promyelocytic leukemia and their management. Int J Hematol 66:13–19.PubMedCrossRefGoogle Scholar
  119. 119.
    Yutsudo Y, Imoto S, Ozuru R, Kajimoto K, Itoi H, Koizumi T, Nishimura R, Nakagawa T. 1997. Acute pancreatitis after all-trans retinoic acid therapy. Ann Hematol 74:295–296. (letter)PubMedCrossRefGoogle Scholar
  120. 120.
    Maruhashi K, Wada H, Taniguchi M, Koizumi S. 1996. Sinus bradyarrhythmia during administration of all-trans retinoic acid in a patient with acute promyelocytic leukemia. Rinsho Ketsueki 37:443–447.PubMedGoogle Scholar
  121. 121.
    Sindermann J, Foerster E, Kienast J. 1996. Severe hepatobiliary complication in a patient with acute promyelocytic leukemia treated with all-trans retinoic acid. Acta Oncol 35:499–501.PubMedGoogle Scholar
  122. 122.
    Escudier SM, Kantarjian HM, Estey EH. 1996. Thrombosis in patients with acute promyelocytic leukemia treated with and without all-trans retinoic acid. Leuk Lymphoma 20:435–439.PubMedCrossRefGoogle Scholar
  123. 123.
    Jimenez-Yuste V, Martin MP, Canales M, Ojeda E, Hernandez-Navarro F. 1997. Pulmonary embolism in a patient with acute promyelocytic leukemia treated with all-trans retinoic acid. Leukemia 11:1988.PubMedGoogle Scholar
  124. 124.
    Frankel SR, Eardley A, Lauwers G, Weiss M, Warrell RP Jr. 1992. The retinoic acid syndrome in acute promyelocytic leukemia. Ann Intern Med 117:292–296.PubMedGoogle Scholar
  125. 125.
    Tallman MS, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, Shepherd L, Andersen JW, Rowe JM, Wiernik PH. 1997. Incidence and clinical course of patients with acute promyelocytic leukemia who develop the retinoic acid syndrome. Blood 90(Suppl 1):416a. (abstract)Google Scholar
  126. 126.
    Cox NH, O’Brien HA. 1994. Sweet’s syndrome associated with trans-retinoic acid treatment in acute promyelocytic leukaemia. Clin Exp Dermatol 19:51–52.PubMedCrossRefGoogle Scholar
  127. 127.
    Piette WW, Trapp JF, O’Donnell MJ, Argenyi Z, Talbot EA, Burns CP. 1994. Acute neutrophilic dermatosis with myeloblastic infiltrate in a leukemia patient receiving all-trans-retinoic acid therapy. J Am Acad Dermatol 30:293–297.PubMedGoogle Scholar
  128. 128.
    Taraboletti G, Borsotti P, Chirivi RG, Vergani V, Falanga A, Barbui T, Giavazzi R, Rambaldi A. 1997. Effect of all trans-retinoic acid (ATRA) on the adhesive and motility properties of acute promyelocytic leukemia cells. Int J Cancer 70:72–77.PubMedCrossRefGoogle Scholar
  129. 129.
    Di Noto R, Lo Pardo C, Schiavone EM, Ferrara F, Manzo C, Vacca C, Del Vecchio L. 1996. All-trans retinoic acid (ATRA) and the regulation of adhesion molecules in acute myeloid leukemia. Leuk Lymphoma 21:201–209.PubMedCrossRefGoogle Scholar
  130. 130.
    Larson RS, Brown DC, Sklar LA. 1997. Retinoic acid induces aggregation of the acute promyelocytic leukemia cell line NB-4 by utilization of LFA-1 and ICAM-2. Blood 90:2747–2756.PubMedGoogle Scholar
  131. 131.
    Evans G, Grimwade D, Prentice HG, Simpson N. 1997. Central nervous system relapse in acute promyelocytic leukaemia in patients treated with all-trans retinoic acid. Br J Haematol 98:437–439.PubMedCrossRefGoogle Scholar
  132. 132.
    Maloisel F, Kurtz JE, Oberling F. 1997. Extramedullary acute promyelocytic leukemia. Cancer 79:2263–2264.PubMedCrossRefGoogle Scholar
  133. 133.
    Currie J, Chee YL, Culligan DJ. 1997. Central nervous system relapse in acute promyelocytic leukaemia treated with ATRA. Br J Haematol 99:469. (letter)PubMedGoogle Scholar
  134. 134.
    Pagano L, Sica S, Marra R, Storti S, Leone G. 1997. Extramedullary relapse in acute promyelocytic leukemia. Leuk Lymphoma 26:417–418. (letter)PubMedGoogle Scholar
  135. 135.
    Tobita T, Shinjyo K, Yanagi M, Takeshita A, Ohnishi K, Ohno R. 1997. Relapse in the external auditory canal of acute promyelocytic leukemia after treatment with all-trans retinoic acid. Intern Med 36:484–486.PubMedGoogle Scholar
  136. 136.
    Eardley AM, Heller G, Warrell RP Jr. 1994. Morbidity and costs of remission induction therapy with all-trans retinoic acid compared with standard chemotherapy in acute promyelocytic leukemia. Leukemia 8:934–939.PubMedGoogle Scholar
  137. 137.
    Takeshita A, Sakamaki H, Miyawaki S, Kobayashi T, Kuriyama K, Yamada O, Oh H, Takenaka T, Asou N, Ohno R. 1995. Significant reduction of medical costs by differentiation therapy with all-trans retinoic acid during remission induction of newly diagnosed patients with acute promyelocytic leukemia. The Japan Adult Leukemia Study Group. Cancer 76:602–608.PubMedCrossRefGoogle Scholar
  138. 138.
    Berman E, Little C, Johnson P, Malbin K, Black P, Gresian D, Harlap S, Parker R, Simone J. 1995. A prospective trial analyzing treatment outcome, financial charges and physician goals in patients with acute leukemia. Blood 86(Suppl 1):516a. (abstract)Google Scholar
  139. 139.
    Kizaki M, Ikeda Y, Tanosaki R, Nakajima H, Morikawa M, Sakashita A, Koeffler HP. 1993. Effects of novel retinoic acid compound, 9-cis-retinoic acid, on proliferation, differentiation, and expression of retinoic acid receptor-alpha and retinoid X receptor-alpha RNA by HL-60 cells. Blood 82:3592–3599.PubMedGoogle Scholar
  140. 140.
    Benedetti L, Levin AA, Scicchitano BM, Grignani F, Allenby G, Diverio D, Lo Coco F, Avvisati G, Ruthardt M, Adamo S, Pelicci PG, Nervi C. 1997. Characterization of the retinoid binding properties of the major fusion products present in acute promyelocytic leukemia cells. Blood 90:1175–1185.PubMedGoogle Scholar
  141. 141.
    Dawson MI, Elstner E, Kizaki M, Chen DL, Pakkala S, Kerner B, Koeffler HP. 1994. Myeloid differentiation mediated through retinoic acid receptor/retinoic X receptor (RXR) not RXR/RXR pathway. Blood 84:446–452.PubMedGoogle Scholar
  142. 142.
    Zhu J, Shi XG, Chu HY, Tong JH, Wang ZY, Naoe T, Waxman S, Chen SJ, Chen Z. 1995. Effect of retinoic acid isomers on proliferation, differentiation and PML relocalization in the APL cell line NB4. Leukemia 9:302–309.PubMedGoogle Scholar
  143. 143.
    Miller WH Jr, Jakubowski A, Tong WP, Miller VA, Rigas JR, Benedetti F, Gill GM, Truglia JA, Ulm E, Shirley M. 1995. 9-cis retinoic acid induces complete remission but does not reverse clinically acquired retinoid resistance in acute promyelocytic leukemia. Blood 85: 3021–3027.PubMedGoogle Scholar
  144. 144.
    Takeshita A, Shibata Y, Shinjo K, Yanagi M, Tobita T, Ohnishi K, Miyawaki S, Shudo K, Ohno R. 1996. Successful treatment of relapse of acute promyelocytic leukemia with a new synthetic retinoid, Am80. Ann Intern Med 124:893–896.PubMedGoogle Scholar
  145. 145.
    Gianni M, Li Calzi M, Terao M, Guiso G, Caccia S, Barbui T, Rambaldi A, Garattini E. 1996. AM580, a stable benzoic derivative of retinoic acid, has powerful and selective cyto-differentiating effects on acute promyelocytic leukemia cells. Blood 87:1520–1531.PubMedGoogle Scholar
  146. 146.
    Tobita T, Takeshita A, Kitamura K, Ohnishi K, Yanagi M, Hiraoka A, Karasuno T, Takeuchi M, Miyawaki S, Ueda R, Naoe T, Ohno R. 1997. Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid. Blood 90:967–973.PubMedGoogle Scholar
  147. 147.
    Takeuchi M, Yano T, Omoto E, Takahashi K, Kibata M, Shudo K, Ueda R, Ohno R, Harada M. 1997. Re-induction of complete remission with a new synthetic retinoid, Am-80, for relapse of acute promyelocytic leukaemia previously treated with all-trans retinoic acid. Br J Haematol 97:137–140.PubMedCrossRefGoogle Scholar
  148. 148.
    Guidez F, Ivins S, Zhu J, Soderstrom M, Waxman S, Zelent A. 1998. Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML-and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia. Blood 91:2634–2642.PubMedGoogle Scholar
  149. 149.
    Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, Zhu J, Tang W, Sun GL, Yang KQ, Chen Y, Zhou L, Fang ZW, Wang YT, Ma J, Zhang P, Zhang TD, Chen SJ, Chen Z, Wang ZY. 1997. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89: 3354–3360.PubMedGoogle Scholar
  150. 150.
    Park JP, Fairweather RB. 1996. Complex t(1;15;17) in acute promyelocytic leukemia with duplication of RAR alpha and PML sequences. Cancer Genet Cytogenet 89:52–56.PubMedCrossRefGoogle Scholar
  151. 151.
    Chen Z, Wang ZY, Chen SJ. 1997. Acute promyelocytic leukemia: cellular and molecular basis of differentiation and apoptosis. Pharmacol Ther 76:141–149.PubMedCrossRefGoogle Scholar
  152. 152.
    Kitamura K, Kiyoi H, Yoshida H, Tobita T, Takeshita A, Ohno R, Naoe T. 1997. New retinoids and arsenic compounds for the treatment of refractory acute promyelocytic leukemia: clinical and basic studies for the next generation. Cancer Chemother Pharmacol 40(Suppl):S36–S41.PubMedCrossRefGoogle Scholar
  153. 153.
    Meloni G, Diverio D, Vignetti M, Avvisati G, Capria S, Petti MC, Mandelli F, Lo Coco F. 1997. Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RAR alpha fusion gene. Blood 90:1321–1325.PubMedGoogle Scholar
  154. 154.
    Roman J, Martin C, Torres A, Jimenez MA, Andres P, Flores R, de la Torre MJ, Sanchez J, Serrano J, Falcon M. 1997. Absence of detectable PML-RAR alpha fusion transcripts in long-term remission patients after BMT for acute promyelocytic leukemia. Bone Marrow Transplant 19:679–683.PubMedCrossRefGoogle Scholar
  155. 155.
    Petkovich M, Brand NJ, Krust A, Chambon P. 1987. A human retinoic acid receptor which belongs to the family of nuclear receptors. Nature 330:444–457.PubMedCrossRefGoogle Scholar
  156. 156.
    Chopra R, Wotherspoon AC, Blair S, McMillan AK, Mills W, Fielding AK, Linch DC, Goldstone AH. 1994. Detection and significance of bone marrow infiltration at the time of autologous bone marrow transplantation in Hodgkin’s disease. Br J Haematol 87:647–649.PubMedGoogle Scholar
  157. 157.
    Aguiar RC, Dahia PL, Bendit, I, Beitler B, Dorlhiac P, Bydlowski S, Chamone D. 1995. Further evidence for the lack of correlation between the breakpoint site within M-BCR and CML prognosis and for the occasional involvement of p53 in transformation. Cancer Genet Cytogenet 84:105–112.PubMedCrossRefGoogle Scholar
  158. 158.
    Kakizuka A, Miller WH Jr, Umesono K, Warrell RP Jr, Frankel SR, Murty VVVS, Dmitrovsky E, Evans RM. 1991. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RARα with a novel putative transcription factor, PML. Cell 66:663–674.PubMedCrossRefGoogle Scholar
  159. 159.
    Collins SJ, Robertson KA, Mueller L. 1990. Retinoic acid-induced granulocytic differentiation of HL-60 myeloid leukemia cells is mediated directly through the retinoic acid receptor (RAR-alpha). Mol Cell Biol 10:2154–2163.PubMedGoogle Scholar
  160. 160.
    Longo L, Pandolfi PP, Biondi A, Rambaldi A, Mencarelli A, Lo Coco F, Diverio D, Pegoraro L, Avanzi G, Tabilio A, Zangrilli D, Alcalay M, Donti E, Grignani F, Pelicci PG. 1990. Rearrangement and aberrant expression of the retinoic acid receptor α gene in acute promyelocytic leukemia. J Exp Med 172:1571–1575.PubMedCrossRefGoogle Scholar
  161. 161.
    Kalantry S, Delva L, Gaboli M, Gandini D, Giorgio M, Hawe N, He LZ, Peruzzi D, Rivi R, Tribioli C, Wang ZG, Zhang H, Pandolfi PP. 1997. Gene rearrangements in the molecular pathogenesis of acute promyelocytic leukemia. J Cell Physiol 173:288–296.PubMedCrossRefGoogle Scholar
  162. 162.
    Shao W, Benedetti L, Lamph WW, Nervi C, Miller WH Jr. 1997. A retinoid-resistant acute promyelocytic leukemia subclone expresses a dominant negative PML-RAR alpha mutation. Blood 89:4282–4289.PubMedGoogle Scholar
  163. 163.
    He LZ, Tribioli C, Rivi R, Peruzzi D, Pelicci PG, Soares V, Cattoretti G, Pandolfi PP. 1997. Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice. Proc Natl Acad Sci USA 94:5302–5307.PubMedCrossRefGoogle Scholar
  164. 164.
    Grisolano JL, Wesselschmidt RL, Pelicci PG, Ley TJ. 1997. Altered myeloid development and acute leukemia in transgenic mice expressing PML-RAR alpha under control of cathepsin G regulatory sequences. Blood 89:376–387.PubMedGoogle Scholar
  165. 165.
    Redner RL, Corey SJ, Rush EA. 1997. Differentiation of t(5;17) variant acute promyelocytic leukemic blasts by all-trans retinoic acid. Leukemia 11:1014–1016.PubMedCrossRefGoogle Scholar
  166. 166.
    Wells RA, Catzavelos C, Kamel-Reid S. 1997. Fusion of retinoic acid receptor alpha to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukaemia. Nat Genet 17:109–113.PubMedCrossRefGoogle Scholar
  167. 167.
    Rosenauer A, Raelson JV, Nervi C, Eydoux P, DeBlasio A, Miller WH Jr. 1996. Alterations in expression, binding to ligand and DNA, and transcriptional activity of rearranged and wild-type retinoid receptors in retinoid-resistant acute promyelocytic leukemia cell lines. Blood 88:2671–2682.PubMedGoogle Scholar
  168. 168.
    Kitamura K, Kiyoi H, Yoshida H, Saito H, Ohno R, Naoe T. 1997. Mutant AF-2 domain of PML-RARalpha in retinoic acid-resistant NB4 cells: differentiation induced by RA is triggered directly through PML-RARalpha and its down-regulation in acute promyelocytic leukemia. Leukemia 11:1950–1956.PubMedCrossRefGoogle Scholar
  169. 169.
    Hong SH, David G, Wong CW, Dejean A, Privalsky ML. 1997. SMRT corepressor interacts with PLZF and with the PML-retinoic acid receptor alpha (RARalpha) and PLZF-RARalpha oncoproteins associated with acute promyelocytic leukemia. Proc Natl Acad Sci USA 94:9028–9033.PubMedCrossRefGoogle Scholar
  170. 170.
    He LZ, Guidez F, Tribioli C, Peruzzi D, Ruthardt M, Zelent A, Pandolfi PP. 1998. Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL. Nat Genet 18:126–135.PubMedCrossRefGoogle Scholar
  171. 171.
    Lin RJ, Nagy L, Inoue S, Shao W, Miller WH Jr, Evans RM. 1998. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 391:811–814.PubMedCrossRefGoogle Scholar
  172. 172.
    Nagy L, Kao HY, Chakravarti D, Lin RJ, Hassig CA, Ayer DE, Schreiber SL, Evans RM. 1997. Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell 89:373–380.PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers, Boston 1999

Authors and Affiliations

  • Stanley R. Frankel
  • Bayard L. Powell

There are no affiliations available

Personalised recommendations